Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-111077 in Treatment-Refractory Advanced Solid Tumors
NCT03158324Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OPB-111077 in solid tumor (advanced stage) and nasopharyngeal carcinoma (NPC), sponsored by National University Hospital. Primary endpoint: Objective Response Rate at 3 years. Status: unknown.
02
Drugs
OPB-111077
03
Conditions
solid tumor (advanced stage)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03158324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158324.